Abstract: A seat assembly for a vehicle seat may have a structural component with multiple reinforcing ribs, a cushion layer, an insert layer which is arranged between the structural component and the cushion layer, at least one component which is secured to the structural component, and at least one securing device. The at least one securing device may secure both the insert part as well as the component to the structural component. A method for assembling such a seat assembly is also described. In one method step, the insert part is secured to the structural component by at least one securing device, and in the same method step or a subsequent method step or a preceding method step the at least one component is secured to the at least one securing device. A vehicle seat have such a seat assembly is also provided.

Abstract: A seat assembly for a vehicle seat may have a structural component with multiple reinforcing ribs, a cushion layer, an insert layer which is arranged between the structural component and the cushion layer, at least one component which is secured to the structural component, and at least one securing device. The at least one securing device may secure both the insert part as well as the component to the structural component. A method for assembling such a seat assembly is also described. In one method step, the insert part is secured to the structural component by at least one securing device, and in the same method step or a subsequent method step or a preceding method step the at least one component is secured to the at least one securing device. A vehicle seat have such a seat assembly is also provided.

Abstract: The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.

Abstract: The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.

Abstract: An encoder encodes digital data, said encoder includes one or more component encoders, one or more interconnections between component encoders, one or more inputs and one or more outputs. The encoder is configured to carry out the following steps: combining internal input bits received via an interconnection and external input bits received via a corresponding input, to assemble a local information word, encoding the local information word such as to generate a local code word, outputting a reduced local code word and handling the same reduced local code word over to the interconnect for forwarding the same reduced local code word to another component encoder or to itself, wherein the encoder is configured to forward on each interconnect the bits of the reduced local code in parallel but with delays that are mutually different for at least a subset of the reduced local code word bits.

Abstract: Disclosed herein is an encoder for encoding digital data, said encoder comprising one or more component encoders, one or more interconnections between component encoders, one or more inputs and one or more outputs. The encoder is configured to carry out the following steps:—combining internal input bits received via an interconnection and external input bits received via a corresponding input, to assemble a local information word,—encoding the local information word such as to generate a local code word,—outputting a reduced local code word and handing the same reduced local code word over to said interconnect for forwarding said same reduced local code word via said interconnect to another component encoder or to itself, wherein said encoder is configured to forward on each interconnect the bits of the reduced local code in parallel but with delays that are mutually different for at least a subset of the reduced local code word bits.

Abstract: The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.

Abstract: The present invention refers to the treatment of asthma by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.

Abstract: The present invention refers to the treatment of asthma by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.